Severe periodontitis has been associated with increased systemic inflammation. In a three-arm preliminary randomized trial, we investigated the impact of standard (SPT) and intensive periodontal therapy (IPT) on serum inflammatory markers and cholesterol levels. Medical and periodontal parameters, C-reactive protein (CRP), interleukin-6 (IL-6), total cholesterol, and LDL cholesterol were evaluated in 65 systemically healthy subjects suffering from severe generalized periodontitis. Two months after treatment, both SPT and IPT resulted in significant reductions in serum CRP compared with the untreated control (0.5 ± 0.2 mg/L for SPT, P = 0.030 and 0.8 ± 0.2 mg/L for IPT, P = 0.001). Similar results were observed for IL-6. Changes in inflammation were independent of age, gender, body mass index, and ethnicity, but a significant interaction between cigarette smoking and treatment regimen was found. The IPT group also showed a decrease in total and LDL cholesterol after 2 months. Analysis of these data indicates that periodontitis causes moderate systemic inflammation in systemically healthy subjects.
Get full access to this article
View all access options for this article.
References
1.
Buhlin K, Gustafsson A, Hakansson J, Klinge B (2002). Oral health and cardiovascular disease in Sweden. J Clin Periodontol29:254–259.
2.
D’Aiuto F, Parkar M, Andreou G, Suvan J, Brett PM, Ready D, et al. (2004). Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res83:156–160.
3.
Ebersole JL, Machen RL, Steffen MJ, Willmann DE (1997). Systemic acute-phase reactants, C-reactive protein and haptoglobin, in adult periodontitis. Clin Exp Immunol107:347–352.
4.
Fernandez-Real JM, Ricart W (2003). Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev24:278–301.
5.
Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. N Engl J Med340:448–454.
6.
Graves DT (1999). The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Clin Infect Dis28:482–490.
7.
Hanes PJ, Purvis JP (2003). Local anti-infective therapy: pharmacological agents. A systematic review. Ann Periodontol8:79–98.
8.
Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ (2000). Identification of periodontal pathogens in atheromatous plaques. J Periodontol71:1554–1560.
9.
Herzberg MC, Weyer MW (1998). Dental plaque, platelets, and cardiovascular diseases. Ann Periodontol3:151–160.
10.
Iacopino AM, Cutler CW (2000). Pathophysiological relationships between periodontitis and systemic disease: recent concepts involving serum lipids. J Periodontol71:1375–1384.
11.
Irwin CR, Myrillas TT (1998). The role of IL-6 in the pathogenesis of periodontal disease. Oral Dis4:43–47.
12.
Iwamoto Y, Nishimura F, Soga Y, Takeuchi K, Kurihara M, Takashiba S, et al. (2003). Antimicrobial periodontal treatment decreases serum C-reactive protein, tumor necrosis factor-alpha, but not adiponectin levels in patients with chronic periodontitis. J Periodontol74:1231–1236.
13.
Katz J, Flugelman MY, Goldberg A, Heft M (2002). Association between periodontal pockets and elevated cholesterol and low density lipoprotein cholesterol levels. J Periodontol73:494–500.
14.
Kluft C, de Maat MP (2001). Determination of the habitual low blood level of C-reactive protein in individuals. Ital Heart J2:172–180.
15.
Kweider M, Lowe GD, Murray GD, Kinane DF, McGowan DA (1993). Dental disease, fibrinogen and white cell count; links with myocardial infarction? Scott Med J38(3):73–74.
16.
Libby P, Ridker PM, Maseri A (2002). Inflammation and atherosclerosis. Circulation105:1135–1143.
17.
Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden V (2000). Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol71:1528–1534.
18.
Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E (2001). Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol72:1221–1227.
19.
Offenbacher S, Farr DH, Goodson JM (1981). Measurement of prostaglandin E in crevicular fluid. J Clin Periodontol8:359–367.
20.
Papapanou PN (1996). Periodontal diseases: epidemiology. Ann Periodontol1:1–36.
21.
Paquette D, Santucci E (2000). A pharmacokinetic study of a locally delivered minocycline therapeutic system (MPTS) (abstract). J Clin Periodontol27(Suppl 1):12.
22.
Paquette D, Oringer R, Lessem J, Offenbacher S, Genco R, Persson GR, et al. (2003). Locally delivered minocycline microspheres for the treatment of periodontitis in smokers. J Clin Periodontol30:787–794.
23.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation107:499–511.
24.
Pocock SJ (1979). Allocation of patients to treatment in clinical trials. Biometrics35:183–197.
25.
Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. (2002). Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. J Am Med Assoc288:980–987.
26.
Pussinen PJ, Jauhiainen M, Vilkuna-Rautiainen T, Sundvall J, Vesanen M, Mattila K, et al. (2004). Periodontitis decreases the antiatherogenic potency of high density lipoprotein. J Lipid Res45:139–147.
27.
Uchiumi D, Kobayashi M, Tachikawa T, Hasegawa K (2004). Subcutaneous and continuous administration of lipopolysaccharide increases serum levels of triglyceride and monocyte chemoattractant protein-1 in rats. J Periodontal Res39:120–128.
28.
Williams RC (1990). Periodontal disease. N Engl J Med322:373–382.
